Summary
Even if the treatment goal in hypertension is ‘the lower the better’, it is obvious that blood pressure (BP) cannot be reduced without reaching a point at which organ perfusion may become compromised and where mortality and morbidity will increase rather than decrease. In 1979, a 5-fold increase in myocardial infarction among patients whose diastolic BP was reduced to below 95mm Hg was reported. In 1987, these results were confirmed, and a J-shaped relationship between diastolic BP and death from myocardial infarction in those patients with evidence of ischaemic heart disease at entry into the trial was shown. In recent years, several studies have demonstrated this J-shaped curve with a J-point between 85 and 91mm Hg. However, all the data were obtained in retrospective analyses of a small number of patients and prospective properly designed studies are necessary before changing our treatment criteria. The Behandla Blodtryck Battre Study fulfils these criteria and preliminary results demonstrate that it is possible to achieve a further reduction in BP in well controlled hypertensive patients without increasing the incidence of side effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Berglund G. Goals of antihypertensive therapy. Is there a point beyond which pressure reduction is dangerous? American Journal of Hypertension 2: 586–593, 1989
Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. British Medical Journal 293: 1145–1151, 1986
Cruickshank JM. Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction. British Medical Journal 297: 1227–1230, 1988
Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1: 581–584, 1987
Hansson L, Dahlof B, Abelin J, for the BBB Study Group. Reduction in blood pressure and adverse effects in the BBB study. Abstracts from the Fifth European Meeting on Hypertension, European Society of Hypertension, Milan, pp. 283, 1991
Hoffman JIE. A critical review of coronary reserve. Circulation 75 (Suppl.): 11–16, 1987
IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). Journal of Hypertension 3: 379–392, 1985
Isles CG, Walker LM, Beevers GD, Brown I, Cameron HL, et al. Mortality in patients of the Glasgow Blood Pressure Clinic. Journal of Hypertension 4: 141–156, 1986
Kannel WB, Stokes III J. Hypertension as a cardiovascular risk factor. In Bulpitt CJ (Ed.) Handbook of hypertension, Vol. 6, Epidemiology of hypertension, pp. 15–34, Elsevier, Amsterdam, 1985
Klocke FJ. Measurements of coronary flow reserve: defining pathophysiology versus making decisions about patient care. Circulation 76: 1183–1189, 1987
Lindholm L, Ejlertsson G, Scherstén B. High risk of cerebrovascular morbidity in well treated male hypertensives. A retrospective study of 40-59-year-old hypertensives in a Swedish primary care district. Acta Medica Scandinavica 216: 251–259, 1984
Lund-Johansen P. Essential hypertension: hemodynamic and therapeutic changes over 20 years. Journal of Cardiovascular Pharmacology 18(Suppl. 4): S1–S7, 1991
MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, et al. Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335: 765–774, 1990
Menard J, Chatellier G, Degoulet P, Plouin PF, Corvol P. How much can blood pressure be lowered? Hypertension 5(Suppl. III): III–21–III–25, 1983
Samuelsson O, Wilhemsen L, Anderson OK, Pennert K, Berglund G. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the Primary Prevention Trial in Goteborg, Sweden. Journal of the American Medical Association 258: 1768–1776, 1987
SHEP Cooperative Research Group. Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). Journal of the American Medical Association 265: 3255–3264, 1991
Staessen J, Bulpitt C, Clement D, De Leeuw P, Fagard R, et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. British Medical Journal 298: 1552–1556, 1989
Stewart IMcDG. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1: 861–865, 1979
Waller PC, Isles CG, Lever AF, Murray GD, McInnes GT. Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease? Journal of Human Hypertension 2: 7–10, 1988
Wilhemsen L, Berglund G, Elmfeldt D, Fitzsimonds T, Holzgreve H, et al. Betablockers versus diuretics in hypertensive men: main results from the HAPPHY trial. Journal of Hypertension 5: 561–572, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Luque-Otero, M., Fernandez-Pinilla, C. The J-Curve. Drugs 44 (Suppl 1), 56–60 (1992). https://doi.org/10.2165/00003495-199200441-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199200441-00010